Washington D.C.-based global science and technology innovator Danaher announced a definitive agreement to acquire Aldevron for $9.6 billion.
The U.S. Supreme Court on June 17 rejected a Republican bid that had been backed by former President Donald Trump’s administration to invalidate Obamacare, preserving the landmark healthcare law for the third time since the ACA’s 2010 enactment.
Medable Inc., a leading cloud platform for patient-centered drug development, announced the hiring of Sanskriti Thakur as chief growth officer.
Seattle-based clinical-stage biopharmaceutical company Lumen Bioscience is teaming up with Novo Nordisk to explore research and development opportunities within obesity, among other metabolic disorders.
Fingerpaint, a full-service health and wellness marketing firm with a global team of more than 580 people, acquired Splice, a healthcare communications business based in Emeryville, California.
Stephen Hahn, the Commissioner of the U.S. Food and Drug Administration under former President Donald Trump, took on a new role as chief medical officer of a new health security initiative launched by Flagship Pioneering, a life sciences venture firm that incubates and curates biopharma companies.
Mary Stutts joined Real Chemistry to lead the global health innovation company’s DE&I strategy, bringing together a unique combination of internal inclusion initiatives with multiple customer-facing efforts across the entire health ecosystem.
Sage Therapeutics’ experimental depression drug showed significant improvement in symptoms compared to placebo in a late-stage study.
WPP company CMI Media Group and Compas – a NMSDC certified diverse supplier that is minority-owned and a part of CMI Media Group – announced executive leadership elevations to drive the next phase of rapid growth, transformation and opportunity for both agencies.
Biopharma company curator Flagship Pioneering, which has launched companies such as Moderna, announced a massive infusion of cash that will be used to support the development and launch of new companies taking aim at a myriad of diseases and global health threats.
